The return of the preclinical IPO? Cancer stem cell firm Verastem raises $55M
This article was originally published in Scrip
Executive Summary
Verastem, a Cambridge, Massachusetts-based preclinical-stage biotech focused on cancer stem research, has been successful with its initial public offering, and raised $55 million by selling 5.5 million shares priced at $10 each, which is the mid-point of the previously outlined price range of $9-11 a piece. The firm has applied for a Nasdaq market listing under the symbol VSTM.